Replies to post #268539 on Avid Bioservices Inc (CDMO)

[Protector]

vinmantoo, this is about Ovarian cancer where actually these vesicles are a TREATMENT TARGET.

The presence of immune suppressive vesicles in the micro environments of ovarian tumors and our ability to block their inhibition of T cell function represent a potential therapeutic target for patients with ovarian cancer.

So the conclusion should not be:

So besides apoptotic cells, there may be another sink to further divert Bavi from target tumor cells.

But Bavituximab can target the PS on these vesicles directly. No new drug needed. And again you would need 12 PS receptor targeting drugs to obtain the SAME effect (after decade of clinical trials and dosageing for 12 combined drugs).